Journal
Nature Medicine
Publication Date
3-1-2024
Volume
30
Issue
3
First Page
716
Last Page
729
Document Type
Open Access Publication
DOI
10.1038/s41591-024-02808-y
Rights and Permissions
Besse, B., Pons-Tostivint, E., Park, K. et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat Med 30, 716–729 (2024). https://doi.org/10.1038/s41591-024-02808-y This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Besse, Benjamin; Morgensztern, Daniel; and et al., "Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: A phase 2 umbrella trial." Nature Medicine. 30, 3. 716 - 729. (2024).
https://digitalcommons.wustl.edu/oa_4/3820
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
